Skip to main content
  • Saved

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis - PubMed

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/32312223/

1 From the TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (R.P.G., E.A.B., S.A.M., M.S.S.). 2 Oslo Universitetssykehus HF, Endocrinology-Morbid Obesity and Preventive Medicine, Norway (T.R.P.). 3 Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine at UCLA, Los Angeles, CA (J.L.S.).